Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05169060 · ClinicalTrials.gov registry record · Phase 1

Omega-3 Fatty Acid Lipidomics in Diabetes Peripheral Neuropathy

A Phase 1 study of Diabetic Neuropathies, sponsored by University of Iowa.

Recruiting
Registry status
Phase 1
Development phase
100
Enrollment target
2
Study locations

NCT05169060: Recruiting Phase 1 study of Diabetic Neuropathies, sponsored by University of Iowa.

NCT05169060 is a Phase 1 study of Diabetic Neuropathies that is actively recruiting participants, run by University of Iowa. The registered enrollment target is 100 participants, below the 316-participant average among 8 other Diabetic Neuropathies trials with a reported enrollment target (68% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05169060, a Phase 1 study of Diabetic Neuropathies, is actively recruiting participants, sponsored by University of Iowa.

RECRUITING
Registry status
Phase 1
Development phase
100 participants
Enrollment target
2
Study locations

Study Summary

Diabetic peripheral neuropathy (DPN) is the most common chronic complication of diabetes, affecting about 50% of patients with diabetes and leading to severe morbidity, poor quality of life, high mortality, and high health care costs. Due to the complex structure and anatomy of the peripheral nervous system, DPN presents with a very broad spectrum of clinical symptoms and deficits, including severe pain, sensory deficits, foot ulcers and amputations. Presently there is no treatment for DPN and even with good blood glucose control DPN develops especially in patients with type 2 diabetes. There is a need to identify effective interventions for DPN. Preclinical studies have provided evidence that the combination of fish oil and salsalate is an effective treatment of DPN. The human subject study to be performed will examine the effect of fish oil with and without salsalate on the blood lipid profile and circulating metabolites of omega-3 polyunsaturated fatty acids (PUFA). Fish oil is an excellent source for the nutrition dependent omega-3 PUFA, primarily eicosapentaenoic acid (EPA; 20:5) and docosahexaenoic acid (DHA; 22:6). These fatty acids are the source of anti-inflammatory metabolites known as resolvin, neuroprotectin and maresin. Preclinical studies have also demonstrated that the metabolites of EPA and DHA are neuroprotective. Furthermore, when fish oil is combined with salsalate the production of these metabolites is increased in vivo. Thus, the investigators hypothesize that fish oil and salsalate will be an effective therapy of DPN. However, prior to doing a formal study of the effect of fish oil + salsalate on DPN there is a need to learn more about what concentration combination will provide the most efficacious effect on the omega-3 index (defined as the sum of EPA and DHA, as a percentage of total fatty acids in red blood cells) and that will safely increase the production of the anti-inflammatory metabolites. These studies will be performed at two sites

Primary Outcome

The omega-3 index is defined as defined as the sum of EPA and DHA, as a percentage of total fatty acids in red blood cells. Red blood cells will be isolated by centrifugation and subsequently analyzed for fatty acid composition following folch extraction of the lipids, derivatization and analysis of the fatty acid profile by gas liquid chromatography. These studies will be done in Dr. Yorek's laboratory.

Conditions Studied

Interventions

  • DRUG Fish Oil Concentrate, 1000 Mg Oral Capsule
  • DRUG Salsalate Oral Tablet

Study Locations (2)

Iowa

  • University of Iowa - Iowa City

Oregon

  • Oregon Health Science University - Portland

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2023-06-12
Est. Completion 2027-07-01
Phase Phase 1
University of Iowa

228 total trials

What NCT05169060 shows while recruiting

NCT05169060 is an interventional study that assigns participants to a tested intervention. The registered 100 participants enrollment target is mid-sized for trials with a published cap, below the 316-participant average among 8 other Diabetic Neuropathies trials with a reported enrollment target (68% lower).

The record links to 1 condition, with Diabetic Neuropathies appearing as the primary indexed condition, and to 2 interventions - of which Fish Oil Concentrate, 1000 Mg Oral Capsule is the first listed.

NCT05169060 reports a single indexed study location in Iowa, Oregon.

Frequently Asked Questions

What is clinical trial NCT05169060 about?

NCT05169060 is a clinical study titled "Omega-3 Fatty Acid Lipidomics in Diabetes Peripheral Neuropathy". Diabetic peripheral neuropathy (DPN) is the most common chronic complication of diabetes, affecting about 50% of patients with diabetes and leading to severe morbidity, poor quality of life, high mortality, and high health care costs. Due to the complex structure and anatomy of the peripheral nervou...

What is the current status of trial NCT05169060?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 100 participants. The study started on 2023-06-12. Estimated completion is 2027-07-01.

What conditions does trial NCT05169060 study?

This clinical trial studies the following conditions: Diabetic Neuropathies.

What interventions are being tested in trial NCT05169060?

The interventions under investigation include: Fish Oil Concentrate, 1000 Mg Oral Capsule (DRUG), Salsalate Oral Tablet (DRUG).

Who is sponsoring clinical trial NCT05169060?

This trial is sponsored by University of Iowa, which has 228 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05169060 being conducted?

This trial has 2 study locations across Iowa, Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Diabetic Neuropathies

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05169060's enrollment target sits among peer trials

100 6th of 8 higher than 3 of 8 other Diabetic Neuropathies trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Diabetic Neuropathies trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01048281 · 100 participants

    Clinical & Pathological Studies of Upper Gastrointestinal Carcinoma

  • NCT01161199 · 100 participants

    The Use of Leukapheresis to Support HIV Pathogenesis Studies

  • NCT01327690 · 100 participants · Early Phase 1

    Mental Health in Veterans and Families After Group Therapies

  • NCT01730781 · 100 participants

    Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05169060, the US trial registry maintained by the National Library of Medicine. NCT05169060 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.